<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03073980</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002465</org_study_id>
    <nct_id>NCT03073980</nct_id>
  </id_info>
  <brief_title>Assessing Efficacy of IV Acetaminophen for Perioperative Pain Control for Oocyte Retrieval</brief_title>
  <official_title>Assessing Efficacy of IV Acetaminophen for Perioperative Pain Control for Oocyte Retrieval: a Randomized, Double Blind, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study we want to learn more about how effective certain medications are at
      reducing pain after oocyte (egg) retrieval surgery and how effective they are at reducing the
      time between the retrieval and discharge from the hospital. We will compare three types of
      pre-operative medications: intravenous (IV) acetaminophen, oral (PO) acetaminophen, and
      placebo (no medication), which is the current typical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVE: To compare the efficacy of pre-operative IV acetaminophen, PO acetaminophen,
      versus placebo for adjunctive pain control in the setting of oocyte retrieval in an in vitro
      fertilization clinic setting.

      HYPOTHESIS: Our hypothesis is that patients receiving IV acetaminophen pre-operatively will
      have improved postoperative pain scores, lower overall opiate consumption, and shortened time
      to discharge from PACU than those receiving PO acetaminophen or placebo.

      Participants will be consented and enrolled in the study prior to their oocyte retrieval. The
      patient will then be randomized to one of three treatments:

      Group 1: In the pre-op suite, these patients will receive 1000mg IV acetaminophen and PO
      placebo, followed by standard protocol anesthesia and pain control as needed.

      Group 2: In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV
      placebo, followed by standard protocol anesthesia and pain control as needed.

      Group 3:

      In the pre-op suite, these patients will receive PO and IV placebo, followed by standard
      protocol anesthesia and pain control as needed.

      The patient and care team will be blinded to the treatment group.

      A member of the study staff will review participants' medical record to collect data
      regarding demographics, clinical history, cycle and pregnancy outcomes, up to 12 months
      following study completion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain control and opiate requirements</measure>
    <time_frame>In PACU and through post-operative day 2</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to discharge from PACU</measure>
    <time_frame>0-6 hours post-procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure length</measure>
    <time_frame>0-2 hours</time_frame>
    <description>Duration of egg retrieval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>0-2 days</time_frame>
    <description>Postoperative nausea and vomiting in PACU and through POD2 (yes/no)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryology outcomes</measure>
    <time_frame>0-7 days</time_frame>
    <description>Oocyte yield, fertilization rate, blastocyst rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy outcomes</measure>
    <time_frame>Up to one year</time_frame>
    <description>Implantation rate, miscarriage rate, pregnancy rate, live birth (&gt;24 weeks gestation) rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Infertility, Female</condition>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Group 1: IV acetaminophen/PO placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the pre-op suite, these patients will receive 1000mg IV acetaminophen and PO placebo, followed by standard protocol anesthesia and pain control as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: IV placebo/PO acetaminophen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In the pre-op suite, these patients will receive 1000mg PO acetaminophen and IV placebo, followed by standard protocol anesthesia and pain control as needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Placebo / Standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>In the pre-op suite, these patients will receive PO and IV placebo, followed by standard protocol anesthesia and pain control as needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Acetaminophen</intervention_name>
    <description>IV Acetaminophen for pain control during procedure</description>
    <arm_group_label>Group 1: IV acetaminophen/PO placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PO Acetaminophen</intervention_name>
    <description>PO Acetaminophen for pain control during procedure</description>
    <arm_group_label>Group 2: IV placebo/PO acetaminophen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo IV Acetaminophen</intervention_name>
    <description>Placebo IV Acetaminophen</description>
    <arm_group_label>Group 2: IV placebo/PO acetaminophen</arm_group_label>
    <arm_group_label>Group 3: Placebo / Standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo PO Acetaminophen</intervention_name>
    <description>Placebo PO Acetaminophen</description>
    <arm_group_label>Group 1: IV acetaminophen/PO placebo</arm_group_label>
    <arm_group_label>Group 3: Placebo / Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        [ ] Patient is 18 years or over, undergoing oocyte retrieval. [ ] Patient is
        English-speaking.

        Exclusion Criteria:

        [ ] Allergy/hypersensitivity to acetaminophen or opiates. [ ] Any history of liver disease,
        history of alcohol depending, or renal impairment as reported in the electronic health
        record.

        [ ] Any history chronic opiate use or chronic pain disorder reported in the electronic
        health record.

        [ ] Weight less than 50kg as reported in the medical record.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabel Chico Calero, PhD</last_name>
    <phone>617-278-1134</phone>
    <email>ichicocalero@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Caitlin Sacha, MD</last_name>
      <phone>617-726-8868</phone>
      <email>csacha@partners.org</email>
    </contact>
    <investigator>
      <last_name>John Petrozza, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caitlin Sacha, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Hsu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 22, 2017</study_first_submitted>
  <study_first_submitted_qc>March 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2017</study_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>John C Petrozza</investigator_full_name>
    <investigator_title>Chief, Division of Reproductive Medicine and IVF, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>in vitro fertilization</keyword>
  <keyword>oocyte retrieval</keyword>
  <keyword>acetaminophen</keyword>
  <keyword>postoperative pain control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

